Sai Ma

Jinan, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications

A real-world data study on long-course venetoclax combined with hypomethylating agents in unfit patients.

A real-world data study on long-course venetoclax combined with hypomethylating agents in unfit patients.

Journal: Frontiers in oncology
Published: March 09, 2026

Superior response and survival of intensive chemotherapy over venetoclax plus azacitidine in newly diagnosed KIT-mutated acute myeloid leukemia.

Superior response and survival of intensive chemotherapy over venetoclax plus azacitidine in newly diagnosed KIT-mutated acute myeloid leukemia.

Journal: Annals of hematology
Published: November 04, 2025

The complement factor B inhibitor iptacopan for relapsed and refractory immune thrombotic thrombocytopenic purpura.

The complement factor B inhibitor iptacopan for relapsed and refractory immune thrombotic thrombocytopenic purpura.

Journal: Thrombosis journal
Published: September 24, 2025

Efficacy and safety of the third-generation tyrosine kinase inhibitor Olverembatinib in relapsed and persistent minimal residual disease positive Philadelphia chromosome-positive acute lymphoblastic leukemia patients.

Efficacy and safety of the third-generation tyrosine kinase inhibitor Olverembatinib in relapsed and persistent minimal residual disease positive Philadelphia chromosome-positive acute lymphoblastic leukemia patients.

Journal: Frontiers in medicine
Published: July 09, 2025

The treatment of autoimmune hemolytic anemia with complement inhibitor iptacopan: a case report.

The treatment of autoimmune hemolytic anemia with complement inhibitor iptacopan: a case report.

Journal: Frontiers in medicine
Published: December 24, 2024

SUMOylation facilitates the stability of BCR-ABL to promote chronic myeloid leukemia progression.

SUMOylation facilitates the stability of BCR-ABL to promote chronic myeloid leukemia progression.

Journal: Oncogene
Published: July 02, 2024

Pan-cancer investigation of RFX family and associated genes identifies RFX8 as a therapeutic target in leukemia.

Pan-cancer investigation of RFX family and associated genes identifies RFX8 as a therapeutic target in leukemia.

Journal: Heliyon
Published: January 30, 2024

Efficacy and safety of flumatinib in the treatment of newly diagnosed chronic myeloid leukemia in the chronic phase: A real-world single-center retrospective study, with a focus on premature drug discontinuation.

Efficacy and safety of flumatinib in the treatment of newly diagnosed chronic myeloid leukemia in the chronic phase: A real-world single-center retrospective study, with a focus on premature drug discontinuation.

Journal: Leukemia research
Published: January 23, 2024

RNA-Binding Protein Lin28B Promotes Chronic Myeloid Leukemia Blast Crisis by Transcriptionally Upregulating miR-181d.

RNA-Binding Protein Lin28B Promotes Chronic Myeloid Leukemia Blast Crisis by Transcriptionally Upregulating miR-181d.

Journal: Molecular cancer research : MCR
Published: November 07, 2023

Successful treatment of systemic mastocytosis with acute myeloid leukemia: a case report.

Successful treatment of systemic mastocytosis with acute myeloid leukemia: a case report.

Journal: Annals of hematology
Published: May 01, 2023

Histone demethylase PHF8 facilitates the development of chronic myeloid leukaemia by directly targeting BCR::ABL1.

Histone demethylase PHF8 facilitates the development of chronic myeloid leukaemia by directly targeting BCR::ABL1.

Journal: British journal of haematology
Published: December 21, 2022

Histone chaperone ASF1A accelerates chronic myeloid leukemia blast crisis by activating Notch signaling.

Histone chaperone ASF1A accelerates chronic myeloid leukemia blast crisis by activating Notch signaling.

Journal: Cell death & disease
Published: May 05, 2022
Showing 1-12 of 19

Last Updated: 09/26/2026